Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Surgery Partners ( (SGRY) ) has issued an announcement.
On November 12, 2025, Surgery Partners, Inc. announced the appointment of Justin Oppenheimer as Chief Operating Officer and National Group President, effective January 1, 2026. Oppenheimer brings a wealth of experience from his previous roles at the Hospital for Special Surgery, which may enhance Surgery Partners’ operational capabilities and strategic positioning in the healthcare sector.
The most recent analyst rating on (SGRY) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Surgery Partners stock, see the SGRY Stock Forecast page.
Spark’s Take on SGRY Stock
According to Spark, TipRanks’ AI Analyst, SGRY is a Neutral.
Surgery Partners’ overall stock score is primarily impacted by its financial performance, which shows strong revenue growth but is hampered by profitability challenges. Technical analysis indicates a bearish trend with oversold conditions, while valuation metrics are unattractive due to negative earnings. The earnings call highlighted growth but also significant challenges, leading to a cautious outlook.
To see Spark’s full report on SGRY stock, click here.
More about Surgery Partners
Surgery Partners, Inc. operates in the healthcare industry, focusing on providing surgical services. The company is known for its network of surgical facilities and partnerships with physicians, aiming to deliver high-quality, cost-effective healthcare solutions.
Average Trading Volume: 1,490,301
Technical Sentiment Signal: Sell
Current Market Cap: $2.07B
For a thorough assessment of SGRY stock, go to TipRanks’ Stock Analysis page.